Invivyd's Q1 Revenue Misses Expectations, Shares Plummet
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IVVD?
Source: stocktwits
- Revenue Decline Factors: H.C. Wainwright & Co. noted that Invivyd's Q1 revenue of $13.7 million, while up 22% year-over-year, fell significantly short of Wall Street's $18 million estimate, indicating that seasonal factors may have impacted performance.
- Surge in R&D Expenses: The reported R&D expenses of $30.7 million exceeded expectations and are seen as a potential reason for the stock's decline, with these costs viewed as pivotal spending in preparation for the upcoming VYD2311 clinical readout.
- Price Target Reaffirmation: Despite revenue pressures, H.C. Wainwright reiterated a 'Buy' rating for Invivyd with a price target of $10, suggesting over 730% upside from current levels, reflecting confidence in the future product pipeline.
- Cautious Market Sentiment: While investor sentiment for IVVD remains neutral, concerns about its future performance have intensified, with some investors warning that without positive Phase 3 trial results, the stock could fall below $1, highlighting significant market uncertainty regarding the company's outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVVD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVVD
Wall Street analysts forecast IVVD stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.160
Low
10.00
Averages
10.00
High
10.00
Current: 1.160
Low
10.00
Averages
10.00
High
10.00
About IVVD
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Invivyd Q1 2026 Earnings Call Highlights
- Accelerated Research Progress: Invivyd initiated the upsizing of its DECLARATION study in early April, with recruitment speed exceeding expectations; although recruitment was temporarily slowed due to anticipated summer COVID waves, it has now resumed at full speed, ensuring the project remains on schedule.
- Monitoring Time Reduction: The Independent Data Monitoring Committee recommended reducing the post-dose monitoring time for drug 2311 from 2 hours to 30 minutes based on safety data review, which could enhance patient acceptance and improve market adoption of the drug.
- Strong PEMGARDA Growth: The company reported a 22% year-over-year growth in PEMGARDA and plans to introduce a new COVID antibody, VYD2311, in the coming months, which, if approved, could significantly alter the market landscape and drive revenue growth.
- Healthy Cash Position: The company raised additional cash in April through market offerings, maintaining a strong cash position, and expects a return to normalized R&D spending as the pivotal trial for VYD2311 concludes, supporting future commercialization efforts.
See More
Invivyd's Q1 Revenue Misses Expectations, Shares Plummet
- Revenue Decline Factors: H.C. Wainwright & Co. noted that Invivyd's Q1 revenue of $13.7 million, while up 22% year-over-year, fell significantly short of Wall Street's $18 million estimate, indicating that seasonal factors may have impacted performance.
- Surge in R&D Expenses: The reported R&D expenses of $30.7 million exceeded expectations and are seen as a potential reason for the stock's decline, with these costs viewed as pivotal spending in preparation for the upcoming VYD2311 clinical readout.
- Price Target Reaffirmation: Despite revenue pressures, H.C. Wainwright reiterated a 'Buy' rating for Invivyd with a price target of $10, suggesting over 730% upside from current levels, reflecting confidence in the future product pipeline.
- Cautious Market Sentiment: While investor sentiment for IVVD remains neutral, concerns about its future performance have intensified, with some investors warning that without positive Phase 3 trial results, the stock could fall below $1, highlighting significant market uncertainty regarding the company's outlook.
See More
Invivyd Reports Q1 2026 Financial Results with Revenue Growth
- Earnings Highlights: Invivyd reported a Q1 2026 GAAP EPS of -$0.13, indicating a loss, yet revenue grew by 21.6% year-over-year to $13.74 million, reflecting a gradual recovery in the company's market position.
- Cash Position: As of the end of Q1 2026, Invivyd had $184.2 million in cash and cash equivalents, ensuring operational funding for the upcoming months, while also planning to raise approximately $20 million through its at-the-market offering facility, enhancing financial flexibility.
- Clinical Progress: Invivyd has made strides in its REVOLUTION clinical program, and while the market reacted positively to updates on its late-stage COVID therapy trial, analysts remain cautious about whether the trial's upsizing will instill the expected market confidence.
- Market Reaction: Following the earnings release, Invivyd's stock price increased, reflecting investor optimism regarding the company's future growth potential, although attention must remain on the final outcomes of its clinical trials and market acceptance.
See More
Invivyd to Announce Q1 Earnings on May 14
- Earnings Announcement Date: Invivyd (IVVD) is set to announce its Q1 earnings on May 14 before market open, with a consensus EPS estimate of -$0.08, reflecting a 42.9% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $18.05 million, representing a 59.7% year-over-year increase, which highlights the company's strong performance in market demand and product sales, likely to positively impact stock prices.
- Estimate Revisions: Over the past three months, both EPS and revenue estimates have seen one upward revision with no downward adjustments, suggesting increased analyst confidence in Invivyd's future performance, which may attract more investor interest.
- Clinical Progress Update: Invivyd has made progress in its REVOLUTION clinical program and plans to release pivotal data for VYD2311 by mid-2026, with this clear timeline helping to bolster market confidence in its R&D pipeline.
See More
Invivyd's Antibody Study Shows Low Side Effects
- Research Findings Released: Invivyd announced results from the EVADE study on low-dose monoclonal antibody adintrevimab, demonstrating minimal tolerability issues, indicating its potential in COVID-19 prevention and possibly altering public expectations regarding vaccine safety.
- Vaccine Comparison Analysis: In comparison with Sanofi's COMPARE study, the protein vaccine showed a Grade 2/3 adverse event rate of 83.6%, while the mRNA vaccine was at 91.6%, indicating a statistical advantage for the protein vaccine in tolerability, which may influence future vaccine choices.
- LIBERTY Trial Launch: Invivyd is set to initiate the LIBERTY trial, which will compare the safety and tolerability of VYD2311 against mRNA vaccines, expected to provide robust data to support vaccination strategies and reinforce the company's leadership in COVID-19 prevention.
- Public Health Challenge: The study highlights the public health challenge of symptom burden post-vaccination, particularly in convincing the public to get vaccinated when most individuals experience discomfort after vaccination, which complicates efforts to encourage COVID-19 protection.
See More
Invivyd Chairman to Speak at Health Summit
- Health Summit Speaker: Marc Elia, Chairman of Invivyd's Board, will speak at the POLITICO Health Care Summit on April 21, discussing the role of monoclonal antibodies in viral disease prevention and their importance in improving American health outcomes.
- Gathering of Policymakers: The summit brings together policymakers, industry leaders, and health experts to explore the future of American healthcare, with Elia's insights potentially influencing future health policies and strategies.
- Monoclonal Antibody Potential: Elia emphasizes that monoclonal antibodies can advance medicine beyond the limits of vaccines, which may spark increased investment and research focus on these therapies, impacting the biopharmaceutical landscape.
- Company Overview: Invivyd is dedicated to developing protection against serious viral infectious diseases and has received FDA emergency use authorization, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
Invivyd Q1 2026 Earnings Call Highlights
- Accelerated Research Progress: Invivyd initiated the upsizing of its DECLARATION study in early April, with recruitment speed exceeding expectations; although recruitment was temporarily slowed due to anticipated summer COVID waves, it has now resumed at full speed, ensuring the project remains on schedule.
- Monitoring Time Reduction: The Independent Data Monitoring Committee recommended reducing the post-dose monitoring time for drug 2311 from 2 hours to 30 minutes based on safety data review, which could enhance patient acceptance and improve market adoption of the drug.
- Strong PEMGARDA Growth: The company reported a 22% year-over-year growth in PEMGARDA and plans to introduce a new COVID antibody, VYD2311, in the coming months, which, if approved, could significantly alter the market landscape and drive revenue growth.
- Healthy Cash Position: The company raised additional cash in April through market offerings, maintaining a strong cash position, and expects a return to normalized R&D spending as the pivotal trial for VYD2311 concludes, supporting future commercialization efforts.
See More
Invivyd's Q1 Revenue Misses Expectations, Shares Plummet
- Revenue Decline Factors: H.C. Wainwright & Co. noted that Invivyd's Q1 revenue of $13.7 million, while up 22% year-over-year, fell significantly short of Wall Street's $18 million estimate, indicating that seasonal factors may have impacted performance.
- Surge in R&D Expenses: The reported R&D expenses of $30.7 million exceeded expectations and are seen as a potential reason for the stock's decline, with these costs viewed as pivotal spending in preparation for the upcoming VYD2311 clinical readout.
- Price Target Reaffirmation: Despite revenue pressures, H.C. Wainwright reiterated a 'Buy' rating for Invivyd with a price target of $10, suggesting over 730% upside from current levels, reflecting confidence in the future product pipeline.
- Cautious Market Sentiment: While investor sentiment for IVVD remains neutral, concerns about its future performance have intensified, with some investors warning that without positive Phase 3 trial results, the stock could fall below $1, highlighting significant market uncertainty regarding the company's outlook.
See More
Invivyd Reports Q1 2026 Financial Results with Revenue Growth
- Earnings Highlights: Invivyd reported a Q1 2026 GAAP EPS of -$0.13, indicating a loss, yet revenue grew by 21.6% year-over-year to $13.74 million, reflecting a gradual recovery in the company's market position.
- Cash Position: As of the end of Q1 2026, Invivyd had $184.2 million in cash and cash equivalents, ensuring operational funding for the upcoming months, while also planning to raise approximately $20 million through its at-the-market offering facility, enhancing financial flexibility.
- Clinical Progress: Invivyd has made strides in its REVOLUTION clinical program, and while the market reacted positively to updates on its late-stage COVID therapy trial, analysts remain cautious about whether the trial's upsizing will instill the expected market confidence.
- Market Reaction: Following the earnings release, Invivyd's stock price increased, reflecting investor optimism regarding the company's future growth potential, although attention must remain on the final outcomes of its clinical trials and market acceptance.
See More
Invivyd to Announce Q1 Earnings on May 14
- Earnings Announcement Date: Invivyd (IVVD) is set to announce its Q1 earnings on May 14 before market open, with a consensus EPS estimate of -$0.08, reflecting a 42.9% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $18.05 million, representing a 59.7% year-over-year increase, which highlights the company's strong performance in market demand and product sales, likely to positively impact stock prices.
- Estimate Revisions: Over the past three months, both EPS and revenue estimates have seen one upward revision with no downward adjustments, suggesting increased analyst confidence in Invivyd's future performance, which may attract more investor interest.
- Clinical Progress Update: Invivyd has made progress in its REVOLUTION clinical program and plans to release pivotal data for VYD2311 by mid-2026, with this clear timeline helping to bolster market confidence in its R&D pipeline.
See More
Invivyd's Antibody Study Shows Low Side Effects
- Research Findings Released: Invivyd announced results from the EVADE study on low-dose monoclonal antibody adintrevimab, demonstrating minimal tolerability issues, indicating its potential in COVID-19 prevention and possibly altering public expectations regarding vaccine safety.
- Vaccine Comparison Analysis: In comparison with Sanofi's COMPARE study, the protein vaccine showed a Grade 2/3 adverse event rate of 83.6%, while the mRNA vaccine was at 91.6%, indicating a statistical advantage for the protein vaccine in tolerability, which may influence future vaccine choices.
- LIBERTY Trial Launch: Invivyd is set to initiate the LIBERTY trial, which will compare the safety and tolerability of VYD2311 against mRNA vaccines, expected to provide robust data to support vaccination strategies and reinforce the company's leadership in COVID-19 prevention.
- Public Health Challenge: The study highlights the public health challenge of symptom burden post-vaccination, particularly in convincing the public to get vaccinated when most individuals experience discomfort after vaccination, which complicates efforts to encourage COVID-19 protection.
See More
Invivyd Chairman to Speak at Health Summit
- Health Summit Speaker: Marc Elia, Chairman of Invivyd's Board, will speak at the POLITICO Health Care Summit on April 21, discussing the role of monoclonal antibodies in viral disease prevention and their importance in improving American health outcomes.
- Gathering of Policymakers: The summit brings together policymakers, industry leaders, and health experts to explore the future of American healthcare, with Elia's insights potentially influencing future health policies and strategies.
- Monoclonal Antibody Potential: Elia emphasizes that monoclonal antibodies can advance medicine beyond the limits of vaccines, which may spark increased investment and research focus on these therapies, impacting the biopharmaceutical landscape.
- Company Overview: Invivyd is dedicated to developing protection against serious viral infectious diseases and has received FDA emergency use authorization, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
